Major depressive disorder （MDD） is a highly heterogeneous disease. Antidepressants are the preferred treatment for MDD， among which selective serotonin reuptake inhibitors （SSRI） and serotonin and norepinephrine reuptake inhibitors （SNRI） are commonly used antidepressants in clinical practice. However， currently clinical medication treatment mainly relies on the clinical experience of doctors， with significant individual differences in efficacy and a lack of objective efficacy evaluation indicators. This article reviews the magnetic resonance neuroimaging features related to the efficacy of SSRI and SNRI， aiming to find the common or specific neuroimaging features that can predict or evaluate the efficacy of SSRI and SNRI antidepressants， so as to provide reference for the individualized and precise treatment， expecting to improve antidepressant effect.